TITLE

Absence of evidence is not evidence of absence

AUTHOR(S)
Alderson, Phil
PUB. DATE
February 2004
SOURCE
BMJ: British Medical Journal (International Edition);2/28/2004, Vol. 328 Issue 7438, p476
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Discusses the need for reporting uncertain results and to report them clearly. Dangers of misinterpreting differences that do not reach significance; Example of a randomised trial; Issue of uncertainty in a study; Difficulties of setting thresholds; Reference to an article by Altman and Bland.
ACCESSION #
12436994

 

Related Articles

  • Calendar of Events.  // Applied Clinical Trials;Aug2004, Vol. 13 Issue 8, p56 

    Presents a calendar of events of interest to clinical trial professionals, compiled as of August 2004. Risk Assessment and Management; 11th Annual Workshop in Japan for Biostatistics; 1st Annual Japan Workshop for Pharmacogenomics.

  • When Averages Hide Individual Differences in Clinical Trials. Kent, David; Hayward, Rodney // American Scientist;Jan/Feb2007, Vol. 95 Issue 1, p60 

    The authors argue that analyzing the results of clinical trials to expose individual patients' could yield more detailed information doctors need to make better treatment decisions. They believe that to be truly useful, clinical trials must routinely include analyses that combine risk factors...

  • When Should Potentially False Research Findings Be Considered Acceptable? Djulbegovic, Benjamin; Hozo, Iztok // PLoS Medicine;Feb2007, Vol. 4 Issue 2, p211 

    Ioannidis estimated that most published research findings are false [1], but he did not indicate when, if at all, potentially false research results may be considered as acceptable to society. We combined our two previously published models [2,3] to calculate the probability above which research...

  • Statistics Notes: Concealing treatment allocation in randomised trials. Altman, Douglas G; Schulz, Kenneth F // BMJ: British Medical Journal (International Edition);8/25/2001, Vol. 323 Issue 7310, p446 

    Discusses the importance of concealing treatment allocation until a patient has entered a randomised clinical trial. Attempts to eliminate bias; How to ensure that allocation sequence will be concealed, including using external help; Difference between randomised and double blind trials.

  • Involving consumers in designing, conducting, and interpreting randomised controlled trials: questionnaire survey. Hanley, Bec; Truesdale, Ann; King, Andy; Elbourne, Diana; Chalmers, Iain // BMJ: British Medical Journal (International Edition);03/03/2001, Vol. 322 Issue 7285, p519 

    Conclusions: Consumer involvement in the design and conduct of controlled trials seems to be growing and seems to be welcomed by most researchers. Such involvement seems likely to improve the relevance to consumers of the questions addressed and the results obtained in controlled trials.

  • Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. Evans; Pocock; Lievre, Michel; Menard, Joel; Bruckert, Eric; Cogneau, Joel; Delahaye, Francois; Giral, Philippe; Leitersdorf, Eran; Luc, Gerald; Masana, Luis; Moulin, Philippe; Passa, Philippe; Pouchain, Denis; Siest, Gerard // BMJ: British Medical Journal (International Edition);03/10/2001, Vol. 322 Issue 7286, p603 

    Discusses premature discontinuation of clinical trial for reasons not related to efficacy, safety or feasibility. Reasons why some trials are discontinued prematurely by their sponsor for strategic reasons; How public financial and scientific participation in some trials and increasing the...

  • Monitoring and Ensuring Safety During Clinical Research. Morse, Michael A.; Califf, Robert M.; Sugarman, Jeremy // JAMA: Journal of the American Medical Association;3/7/2001, Vol. 285 Issue 9, p1201 

    Addresses concerns regarding the protection of human subjects in clinical trials. Description of the manner in which adverse event reporting might function to enhance safety; Role of data monitoring committees in using aggregate data from these reports; Problems that exist for institutional...

  • Intention-to-treat analysis: Protecting the integrity of randomization. Mahaniah, Kiame J.; Rao, Goutham // Journal of Family Practice;Aug2004, Vol. 53 Issue 8, p644 

    Randomization is a crucial part of most clinical trials. The purpose of randomization in a trial comparing 2 groups is to ensure that the groups differ only with respect to the interventions being compared. Randomization determines not only which treatment subjects receive, but also how the...

  • CONSORT statement: extension to cluster randomised trials. Campbell, Marion K.; Elbourne, Diana R.; Altman, Douglas G. // BMJ: British Medical Journal (International Edition);3/20/2004, Vol. 328 Issue 7441, p702 

    Offers a look at the effective reporting of randomized controlled trials. Guidelines in the Consolidated Standards of Reporting Trials (CONSORT) statement; Discussion of methodological issues in cluster randomized trials; Quality of reporting of cluster trials; Extension of CONSORT statement to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics